There is considerable interest in the development of targeted therapies against DLL3, including antibody–drug conjugates (ADCs) and engineered T cell therapies (e.g., chimeric antigen receptor T), both relying on the selective expression of DLL3 in cancer cells, allowing the targeted delivery of therapeutic agents directly to the tumor. Here, DLL3 is linked to cancer.